Medical Condition News

RSS

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

University of Houston physicists are using complex computer simulations to illuminate the workings of a crucial protein that, when malfunctioning, may cause Alzheimer's and cancer.

20 Nov 2010

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

The first American study that positions Platelet Rich Plasma Therapy (PRP) as a viable means in managing knee osteoarthritis, appeared today in the December issue of the American Journal of Physical Medicine & Rehabilitation (AJPMR). The study, authored by Dr. Steven Sampson of the Orthohealing Center in Los Angeles, details the account of 14 patients with primary and secondary knee osteoarthritis receiving three platelet-rich plasma injections in the affected knee at 4-week intervals with one year follow up.

20 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

Discovery could provide new approaches to treat metabolic disorders

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.

20 Nov 2010

Study highlights poor outcomes for patients with ESRD admitted over weekend

Patients with end-stage renal disease who are admitted to the hospital during the weekend are at increased risk of death, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

NJISA experts to discuss science, impact and current state of Alzheimer's disease in America

The New Jersey Institute for Successful Aging (NJISA) at the UMDNJ-School of Osteopathic Medicine, one of the country's leading providers of geriatric care, research and education, is making experts available who can discuss the science, impact and current state of Alzheimer's disease in America.

20 Nov 2010

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA has also informed the generic manufacturers of propoxyphene-containing products of Xanodyne's decision and requested that they voluntarily remove their products as well.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.

20 Nov 2010

Consuming a variety of fruit reduces lung cancer risk by 23%

Eating five portions of fruit and vegetables per day is one of the means that experts most frequently recommend for preventing cancer. Now, the European EPIC study carried out by researchers from 10 countries has shown that, in the case of lung cancer, the important thing is not just the quantity but also the variety of fruit consumed, which can reduce the risk by up to 23%.

20 Nov 2010

Medtronic's Valiant Stent System effective for thoracic aortic aneurysms treatment

An implantable medical device used in the minimally invasive treatment of thoracic aortic aneurysms, the Valiant Thoracic Stent Graft System from Medtronic, Inc., delivered strong results through 30 days of patient follow-up in the company's U.S. pivotal study, according to clinical data presented at VEITHsymposium.

19 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

Task Force for National Conference on Diabetes issues Call to Action to improve diabetes care

The Task Force for the National Conference on Diabetes issued a Call to Action today entitled Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact. This Call to Action is a result of the National Conference on Diabetes, held earlier this year in Washington, D.C., which was attended by nearly 100 participants representing the Administration, Congress, government officials, public health organizations and industry.

19 Nov 2010

Boston Scientific's CRT-Ds, ICDs receive CE Mark approval

Boston Scientific Corporation today announced CE Mark approval of its INCEPTA, ENERGEN and PUNCTUA cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators.

19 Nov 2010

Substance abuse treatment facilities offering nicotine replacement therapy increased by 6%: Report

The percentage of substance abuse treatment facilities offering nicotine replacement therapy to clients gradually increased by about 6 percentage points from 2006 to 2009, according to a new Spotlight report issued by the Substance Abuse and Mental Health Services Administration released in conjunction with the "Great American Smokeout."

19 Nov 2010

Medical Condition News

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Discovery could provide new approaches to treat metabolic disorders

Study highlights poor outcomes for patients with ESRD admitted over weekend

NJISA experts to discuss science, impact and current state of Alzheimer's disease in America

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Consuming a variety of fruit reduces lung cancer risk by 23%

Medtronic's Valiant Stent System effective for thoracic aortic aneurysms treatment

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Task Force for National Conference on Diabetes issues Call to Action to improve diabetes care

Boston Scientific's CRT-Ds, ICDs receive CE Mark approval

Substance abuse treatment facilities offering nicotine replacement therapy increased by 6%: Report

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News